Table 1.

Summary of patient characteristics (safety population) who entered the treatment period.

Characteristic	Placebo	Fermagate 1 g	Fermagate 2 g	Total
N	21	21	21	63
Age (yr)
mean	58.6	60.6	58.1	59.1
SD	13.8	15.2	14.0	14.2
median	61.0	64.0	54.0	61.0
range	[28 to 84]	[31 to 84]	[34 to 81]	[28 to 84]
Gender
female	5 (23.8%)	5 (23.8%)	8 (38.1%)	18 (28.6%)
male	16 (76.2%)	16 (76.2%)	13 (61.9%)	45 (71.4%)
Race/ethnicity
Caucasian	20 (95.2%)	19 (90.5%)	18 (85.7%)	57 (90.5%)
Asian	1 (4.8%)	2 (9.5%)	0 (0.0%)	3 (4.8%)
black, of African origin	0 (0.0%)	0 (0.0%)	3 (14.3%)	3 (4.8%)